CSPC Pharmaceutical Group Limited CVG.F Stock
CSPC Pharmaceutical Group Limited Price Chart
CSPC Pharmaceutical Group Limited CVG.F Financial and Trading Overview
CSPC Pharmaceutical Group Limited stock price | 0.7 EUR |
Previous Close | 0.77 EUR |
Open | 0.8 EUR |
Bid | 0.79 EUR x 1500000 |
Ask | 0.84 EUR x 1500000 |
Day's Range | 0.8 - 0.8 EUR |
52 Week Range | 0.76 - 1.25 EUR |
Volume | 2.5K EUR |
Avg. Volume | 819 EUR |
Market Cap | 9.81B EUR |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 11.402857 |
EPS (TTM) | 0.06 EUR |
Forward Dividend & Yield | 0.03 (3.40%) |
Ex-Dividend Date | June 5, 2023 |
1y Target Est | N/A |
CVG.F Valuation Measures
Enterprise Value | 9.01B EUR |
Trailing P/E | 11.402857 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.31499606 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
CSPC Pharmaceutical Group Limited Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -14.85% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.25 EUR |
52 Week Low | 0.76 EUR |
50-Day Moving Average | 0.87 EUR |
200-Day Moving Average | 0.99 EUR |
CVG.F Share Statistics
Avg. Volume (3 month) | 819 EUR |
Avg. Daily Volume (10-Days) | 855 EUR |
Shares Outstanding | 11.9B |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 29.59% |
% Held by Institutions | 33.11% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | 164.00% |
Payout Ratio | 0.3424 |
Last Split Factor | 8:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | 2.6 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | 0.07 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | 2.534 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of CSPC Pharmaceutical Group Limited
Country | Germany |
State | N/A |
City | Shijiazhuang |
Address | No. 226 Huanghe Street |
ZIP | 050035 |
Phone | 86 31 1870 37015 |
Website | https://www.cspc.com.hk |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 24837 |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. The company was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Q&A For CSPC Pharmaceutical Group Limited Stock
What is a current CVG.F stock price?
CSPC Pharmaceutical Group Limited CVG.F stock price today per share is 0.7 EUR.
How to purchase CSPC Pharmaceutical Group Limited stock?
You can buy CVG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CSPC Pharmaceutical Group Limited?
The stock symbol or ticker of CSPC Pharmaceutical Group Limited is CVG.F.
Which industry does the CSPC Pharmaceutical Group Limited company belong to?
The CSPC Pharmaceutical Group Limited industry is Drug Manufacturers-General.
How many shares does CSPC Pharmaceutical Group Limited have in circulation?
The max supply of CSPC Pharmaceutical Group Limited shares is 12.08B.
What is CSPC Pharmaceutical Group Limited Price to Earnings Ratio (PE Ratio)?
CSPC Pharmaceutical Group Limited PE Ratio is 11.60666700 now.
What was CSPC Pharmaceutical Group Limited earnings per share over the trailing 12 months (TTM)?
CSPC Pharmaceutical Group Limited EPS is 0.06 EUR over the trailing 12 months.
Which sector does the CSPC Pharmaceutical Group Limited company belong to?
The CSPC Pharmaceutical Group Limited sector is Healthcare.